Caris Life Sciences Highlights the Importance of DPYD Testing in Colorectal Cancer During Colorectal Cancer Awareness Month

Caris Life Sciences® (NASDAQ: CAI), a leading patient-centric, next-generation AI TechBio company and precision medicine ...

Caris Life Sciences (CAI) expands AI insights portfolio with signature to predict ovarian cancer platinum resistance

Caris Life Sciences Inc. (NASDAQ:CAI) is one of the best NASDAQ stocks under $30 to buy. On March 16, Caris Life Sciences expanded its Caris AI Insights portfolio with a new AI signature designed to ...
TMCnet

Caris Life Sciences to Showcase Five Studies at the 2026 USCAP Annual Meeting

Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that the company and collaborators from leading ...
ascopubs.org

Costs and Benefits of Whole-Exome, Whole-Transcriptome Sequencing in Patients With Advanced Non–Small Cell Lung Cancer

Functional Characterization of Variants of Unknown Significance of Fibroblast Growth Factor Receptors 1-4 and Comparison With AI Model–Based Prediction An economic model was developed to estimate the ...
technologynetworks

How To Obtain Robust Whole Transcriptome Sequencing From FFPE Samples

Precision oncology is shifting toward comprehensive transcriptome profiling to reveal fusions, splice variants, and expression changes that DNA panels miss. Yet obtaining reliable data from degraded ...
Healthcare IT News

AI to power Singapore's next-gen cancer profiling test

A $4.7 million collaboration led by the National Cancer Centre Singapore will develop a clinical-grade test using AI and ...
Baylor College of Medicine

Baylor researchers develop and validate clinical diagnostic RNA sequencing test

RNA sequencing has emerged as a powerful supplement to DNA sequencing for Mendelian disease diagnosis, but clinical translation of diagnostic RNA-seq has not been widely achieved. Researchers at ...